TYME - Tyme Technologies rises on pipeline update

MicroStockHub/E+ via Getty Images Tyme Technologies (TYME) has risen ~13.2% in extended trading after announcing  Q4 and full year financials for fiscal 2021 today. The basic and diluted loss per share has increased ~15.7% YoY to ~$0.22 in FY21 while cash  and cash equivalents reached ~$107.5M more than fourfold rise from $26.7M in the previous year. The company also gave an update on its clinical development program following a strategic review. It has launched a Phase 2 breast cancer trial named OASIS in partnership with Georgetown University. The investigator-initiated prospective open-label study is designed to evaluate SM-88 in metastatic hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer after treatment with a CDK4/6 inhibitor, the company said. The trial targeting the commonest form of breast cancers in the U.S. is expected to enroll 30 patients with potential expansion up to a total of 50 patients. As a result

For further details see:

Tyme Technologies rises on pipeline update